Nanjing Zenshine Pharmaceuticals Co , Ltd (Zenshine) announced that NMPA has approved their IND application of ZX-7101A to progress a phase 1 clinical study for the treatment of Influenza virus infection
IASO Biotherapeutics (IASO Bio), a clinical-stage biopharmaceutical company advancing the development of novel cell therapies for cancer, today announced the clearance from China’s National Medical Products Administration (NMPA) of two Initial New Drug
On August 2, 2021, Nanjing Leadsbiolab Biotechnology Co , Ltd (hereinafter referred to as "Leadsbiolab ")has announced that its LBL-024 for PD-L1 4-1BB bispecific antibody injection was approved by the U S FDA for Clinical trail!
PharmaBlock joins the Forbes China List of 2021 Top 50 Most Innovative Companies! It affirms the company s contribution to the industry through innovative products, technologies, business models, and its robust business growth